Promising novel therapies and platforms for neurological disorders are emerging. Aerska launched with $21 million seed funding to develop RNAi drugs targeting the brain, advancing treatments for neurodegenerative diseases. Mercury Bio presented preclinical data showing effective protein delivery into neurons via yeast-derived extracellular vesicles. IL-6 and LRRK2 biomarkers gain prominence with new neurodegeneration panels for plasma analysis, enabling better diagnosis and monitoring. These advances could transform treatment approaches for conditions like Parkinson’s and ALS.